Risk Disclaimer - By using this web site you agree to its terms and conditions.
All materials, including but not limited to articles, directories, photos, lists, etc., on this website are the sole property of ForexTV or the respective copyright holders and are intended for informational/educational purposes using hypothetical and sometimes anecdotal illustrations. The unauthorized use of any and all materials is prohibited and restricted by copyright law. Any use of materials on this site must be approved in advance by ForexTV.
Before deciding to invest in foreign exchange you should carefully consider your investment objectives, level of experience, and risk appetite. The possibility exists that you could sustain a loss of some or all of your initial investment and therefore you should not invest money that you cannot afford to lose. You should be aware of all the risks associated with foreign exchange trading, and seek advice from an independent financial advisor if you have any
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
DAXOR CORPORATION AWARDED GRANT FROM THE CENTER FOR ADVANCING POINT OF CARE TECHNOLOGIES .
Daxor CorporationFebruary 5, 2021 GMT
NEW YORK, Feb. 05, 2021 (GLOBE NEWSWIRE) Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, announces today that it has been awarded a grant from the Center for Advancing Point of Care Technologies (CAPCaT), a program run by the Massachusetts Medical Device Development Center (M2D2) funded by the National Heart, Lung, and Blood Institute and the National Center for Complementary and Integrative Health, both part of the National Institutes of Health (NIH), to develop a smart, point-of-care heart failure diagnostic for quantification of intravascular fluid overload to enable precision diuretic dosing.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Daxor to Present at the Inaugural H.C. Wainwright BioConnect 2021 Conference
Daxor CorporationJanuary 8, 2021 GMT
NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology (organized as an investment company with fully-owned innovative medical instrumentation and biotechnology operations), today announces that Michael Feldschuh, Daxor’s President & Chief Executive Officer, will present at the inaugural H.C. Wainwright BioConnect Investment Conference which is being held from January 11th to 14th through a virtual format with on-demand video presentations.